AlphaCrest Capital Management’s Amicus Therapeutics FOLD Stock Holding History

AlphaCrest Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-35,652	Closed	-$372K	–	434
2022 Q3	$372K	Buy	+35,652	New	+$397K	0.02%	1078
2022 Q1	–	Sell	-16,678	Closed	-$193K	–	1302
2021 Q4	$193K	Sell	16,678 -52,895	-76%	-$589K	0.01%	1337
2021 Q3	$664K	Buy	69,573 +32,212	+86%	+$330K	0.03%	795
2021 Q2	$360K	Sell	37,361 -32,678	-47%	-$319K	0.02%	1062
2021 Q1	$692K	Buy	70,039 +59,975	+596%	+$928K	0.04%	655
2020 Q4	$232K	Buy	+10,064	New	+$206K	0.02%	1015
2020 Q1	–	Sell	-22,982	Closed	-$224K	–	1104
2019 Q4	$224K	Buy	22,982 +4,973	+28%	+$45.5K	0.02%	1177
2019 Q3	$144K	Buy	+18,009	New	+$195K	0.01%	1232

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

AlphaCrest Capital Management's FOLD Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Amicus Therapeutics (FOLD) in Q4 2022, closing a stake of 35,652 shares — an estimated $372K sold.

AlphaCrest Capital Management first reported a position in FOLD in Q3 2019 and held it in 8 quarters. The position peaked at $692K in Q1 2021. 230 funds tracked by Wall St. Rank hold FOLD as of Q4 2022.

AlphaCrest Capital Management reported no remaining Amicus Therapeutics position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 35,652 Amicus Therapeutics shares in Q4 2022, an estimated $372K.
AlphaCrest Capital Management first reported a position in Amicus Therapeutics in Q3 2019 and held it in 8 quarters.
AlphaCrest Capital Management's Amicus Therapeutics position peaked at $692K in Q1 2021.
230 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.